论文部分内容阅读
小细胞肺癌(SCLC)是肺癌中发展最迅速的一种,其发病率仅次于鳞癌和腺癌,约占全部肺癌20～30%。SCLC在病因学、种系发生学、组织病理学、临床和生物学诸方面都有明显特征。就生物学和临床特点而言,有早期和广泛播散的倾向,确诊时2/3以上已有广泛转移,因而手术切除几乎不可能。以往长期(2年)无病生存率仅2%左右。但SCLC对化疗和放疗比较敏感,近10年来在治疗上取得了新的进展,总的预后情况(表现在存活期和生存质量)均有显著改善。本文就SCLC近
Small cell lung cancer (SCLC) is the most rapidly developing type of lung cancer. Its incidence is second only to squamous cell carcinoma and adenocarcinoma, accounting for about 20-30% of all lung cancers. SCLC has obvious features in etiology, phylogeny, histopathology, clinical and biological aspects. In terms of biological and clinical characteristics, there is a tendency for early and widespread dissemination, with more than two-thirds of diagnoses already having extensive metastases, and surgical resection is therefore almost impossible. The previous long-term (2-year) disease-free survival rate was only about 2%. However, SCLC is sensitive to chemotherapy and radiotherapy, and has made new progress in treatment in the past 10 years. The overall prognosis (expressed in survival and quality of life) has improved significantly. This article is about SCLC